Corona remedies limited IPO Overview
Corona remedies limited IPO is a Mainboard public issue offered through a Book Building issue with a total issue size of ₹655.37 Cr. The IPO price band is set at ₹1008 to ₹1062 per share, and retail investors can apply with a minimum investment of ₹14,868 as per IPO guidelines.
The Corona remedies limited IPO opens on 8 Dec 2025 and closes on 10 Dec 2025. The IPO allotment is expected to be finalized on 11 Dec 2025, and the equity shares are proposed to be listed on BSE,NSE on 15 Dec 2025.
Investors can refer to the Corona remedies limited IPO RHP-DRHP for detailed information. The issue is managed by JM Financial Ltd.,IIFL Capital Services Ltd.,Kotak Mahindra Capital Co.Ltd. as the book running lead manager, while Bigshare Services Pvt Ltd is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About corona remedies limited
As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per
annum.
Competitive Strength:
Second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market.
Demonstrated capabilities of building a diversified portfolio, including “engine” brands, in our targeted therapy areas.
Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market.
Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
Qualified, experienced and entrepreneurial management team supported by marquee investors.